
GreenLight Biosciences celebrates manufacturing milestone for Covid-19 booster candidate
It was late last year when the biotech GreenLight Biosciences inked a deal with CDMO giant Samsung Biologics to manufacture its mRNA Covid-19 vaccine. Now, as Samsung pumps more money into its biotech and CDMO operations, the South Korean company has completed the first commercial-scale engineering run for GreenLight’s Covid-19 vaccine booster candidate.
According to Samsung Biologics, GreenLight’s synthesis reaction had a titer of 12g/L at a commercial scale and produced 650g of mRNA. On the back of this test, GreenLight’s Covid booster is expected to have data later this year, with manufacturing at a commercial scale starting soon after.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.